Dare BioscienceDARE
DARE
About: Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Employees: 23
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
0.57% more ownership
Funds ownership: 8.93% [Q4 2024] → 9.51% (+0.57%) [Q1 2025]
1% less capital invested
Capital invested by funds: $2.43M [Q4 2024] → $2.39M (-$34.9K) [Q1 2025]
4% less funds holding
Funds holding: 25 [Q4 2024] → 24 (-1) [Q1 2025]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$12
296%
upside
Avg. target
$12
296%
upside
High target
$12
296%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Douglas Tsao | 296%upside $12 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 days ago
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders
SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that the company's 2025 annual meeting of stockholders (the “Annual Meeting”) was convened and adjourned without any business conducted due to lack of the required quorum. A quorum is necessary to hold the Annual Meeting.
Neutral
Seeking Alpha
1 month ago
Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript
Daré Bioscience, Inc. (NASDAQ:DARE ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - President & Chief Executive Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Operator Welcome to the Conference Call hosted by Daré Bioscience to review the company's First Quarter 2025 Financial Results and to provide the Business Update.
Negative
Zacks Investment Research
1 month ago
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.84 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update
In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probiotics in 2025 and its proprietary monthly hormone therapy in 2026 In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probiotics in 2025 and its proprietary monthly hormone therapy in 2026
Neutral
Seeking Alpha
2 months ago
Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript
Daré Bioscience, Inc. (NASDAQ:DARE ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - President & Chief Executive Officer Conference Call Participants Catherine Novack - Jones Trading Douglas Tsao - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets Operator Welcome to the conference call hosted by Daré Bioscience to review the company's 2024 Financial Results and to provide a Business Update.
Negative
Zacks Investment Research
2 months ago
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.72 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
With increasing demand for needed treatments designed for women, Daré is taking action to make its proprietary Sildenafil Cream formulation available via prescription this year With increasing demand for needed treatments designed for women, Daré is taking action to make its proprietary Sildenafil Cream formulation available via prescription this year
Neutral
GlobeNewsWire
2 months ago
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, March 31, 2025, to review its financial results for the year ended December 31, 2024, and to provide a company update.
Neutral
GlobeNewsWire
4 months ago
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management
Neutral
GlobeNewsWire
5 months ago
Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
The panel will discuss the value proposition for investing in women's health. J.P. Morgan is hosting a three-panel women's health series at this year's conference to highlight the importance of innovation and growing visibility around women's health.
Charts implemented using Lightweight Charts™